Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jvir.2014.02.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exercise training partly ameliorates cardiac dysfunction in mice during doxorubicin treatment of breast cancer.
J Transl Med
January 2025
Department of Biology, University of Turku, Turku, Finland.
Introduction: Doxorubicin is a chemotherapeutic drug used to treat various cancers. Exercise training (ET) can attenuate some cardiotoxic effects of doxorubicin (DOX) in tumor-free animals. However, the ET effects on cardiac function and glucose metabolism in DOX-treated breast cancer models remain unclear.
View Article and Find Full Text PDFTranscription factor EB (TFEB) activity increases resistance of TNBC stem cells to metabolic stress.
Life Sci Alliance
March 2025
https://ror.org/00hj54h04 Interdisciplinary Life Sciences Graduate Programs, The University of Texas at Austin, Austin, TX, USA
Breast cancer stem cells (CSCs) are difficult to therapeutically target, but continued efforts are critical given their contribution to tumor heterogeneity and treatment resistance in triple-negative breast cancer. CSC properties are influenced by metabolic stress, but specific mechanisms are lacking for effective drug intervention. Our previous work on TFEB suggested a key function in CSC metabolism.
View Article and Find Full Text PDFHPA axis dysregulation and postpartum depression and anxiety symptoms in breastfeeding vs bottle-feeding parents.
Psychoneuroendocrinology
November 2024
Department of Psychiatry, University of North Carolina School of Medicine, USA.
Objective: Hypothalamic-pituitary-adrenal (HPA) axis dysregulation has been implicated in the pathogenesis of perinatal mood disorders. Further, HPA axis response is known to be blunted during breastfeeding. We hypothesized that 1) postpartum depression/anxiety symptoms would be associated with HPA axis dysregulation, indexed by loss of expected adrenocorticotropic hormone (ACTH)-cortisol coupling, and 2) this association would vary by method of infant feeding.
View Article and Find Full Text PDFPolyanhydride Copolymer-Based Niclosamide Nanoparticles for Inhibiting Triple-Negative Breast Cancer: Metabolic Responses and Synergism with Paclitaxel.
ACS Appl Mater Interfaces
December 2024
Department of Chemical and Biological Engineering, Iowa State University, Ames, Iowa50011, United States.
The heterogeneity of tumors and the lack of effective therapies have resulted in triple-negative breast cancer (TNBC) exhibiting the least favorable outcomes among breast cancer subtypes. TNBC is characterized by its aggressive nature, often leading to high rates of relapse, metastasis, and mortality. Niclosamide (Nic), an Food and Drug Administration-approved anthelmintic drug, has been repurposed for cancer treatment; however, its application for TNBC is hindered by significant challenges, including strong hydrophobicity, poor aqueous solubility, and low bioavailability.
View Article and Find Full Text PDFPost-COVID immunity in patients with solid tumor or hematological malignancies treated with SARS-CoV-2 monoclonal antibodies.
Immun Inflamm Dis
December 2024
Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Article Synopsis
- - The study investigates how SARS-CoV-2 monoclonal antibody (mAB) therapy affects the immune response in five cancer patients infected with the virus, comparing them to non-mAB-treated controls.
- - Blood samples were analyzed for various immune responses, revealing that all patients produced antibodies and T-cell responses similar to those of controls, despite some having B-cell deficiencies.
- - The findings indicate that mAB therapy results in a robust immune response against SARS-CoV-2 in cancer patients, showing the potential for effective protective immunity even with underlying malignancies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!